Literature DB >> 14592908

The epidemiology of myasthenia gravis.

Lawrence H Phillips1.   

Abstract

Population-based studies of the epidemiology of myasthenia gravis (MG) have been conducted for over 50 years. Over that time, there has been a clear trend towards an increase in the reported prevalence of the disease. In recent years, there has also been an interest in determining a reasonably accurate estimate of the number of MG patients in the United States. Current estimates place the prevalence at a high value of about 20 per 100,000. The year 2000 U.S. population estimate is slightly less than 280 million. A crude estimate of the number of MG patients derived from the population estimate and the reported prevalence from selected populations indicates that there are between 53,000 and 59,900 patients in the United States at this time. The age and ethnic distributions in the United States are evolving from those that were present when the majority of the population-based studies were done, and the distribution of severity of the disease may also have changed. Future studies of the epidemiology of MG should take these factors into account, and further research into the economic and quality-of-life impact of the disease in the population is needed.

Entities:  

Mesh:

Year:  2003        PMID: 14592908     DOI: 10.1196/annals.1254.053

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  46 in total

1.  Nationwide population-based epidemiological study of myasthenia gravis in taiwan.

Authors:  Chien-Hsu Lai; Hung-Fu Tseng
Journal:  Neuroepidemiology       Date:  2010-06-03       Impact factor: 3.282

Review 2.  Diagnosis and management of autoimmune myasthenia gravis.

Authors:  Corrado Angelini
Journal:  Clin Drug Investig       Date:  2011       Impact factor: 2.859

Review 3.  Mechanisms underlying autoimmune synaptic encephalitis leading to disorders of memory, behavior and cognition: insights from molecular, cellular and synaptic studies.

Authors:  Emilia H Moscato; Ankit Jain; Xiaoyu Peng; Ethan G Hughes; Josep Dalmau; Rita J Balice-Gordon
Journal:  Eur J Neurosci       Date:  2010-07-14       Impact factor: 3.386

4.  Dysregulation of B Cell Repertoire Formation in Myasthenia Gravis Patients Revealed through Deep Sequencing.

Authors:  Jason A Vander Heiden; Panos Stathopoulos; Julian Q Zhou; Luan Chen; Tamara J Gilbert; Christopher R Bolen; Richard J Barohn; Mazen M Dimachkie; Emma Ciafaloni; Teresa J Broering; Francois Vigneault; Richard J Nowak; Steven H Kleinstein; Kevin C O'Connor
Journal:  J Immunol       Date:  2017-01-13       Impact factor: 5.422

Review 5.  Treatment of myasthenia gravis: focus on pyridostigmine.

Authors:  Lorenzo Maggi; Renato Mantegazza
Journal:  Clin Drug Investig       Date:  2011-10-01       Impact factor: 2.859

6.  Antibodies against low-density lipoprotein receptor-related protein 4 induce myasthenia gravis.

Authors:  Chengyong Shen; Yisheng Lu; Bin Zhang; Dwight Figueiredo; Jonathan Bean; Jiung Jung; Haitao Wu; Arnab Barik; Dong-Min Yin; Wen-Cheng Xiong; Lin Mei
Journal:  J Clin Invest       Date:  2013-11-08       Impact factor: 14.808

7.  Efficacy of tacrolimus against Churg-Strauss syndrome in a patient with myasthenia gravis.

Authors:  Shiro Niiyama; Yasuyuki Amoh; Kosuke Suzuki; Tatsuhiko Wada; Kensei Katsuoka
Journal:  Rheumatol Int       Date:  2009-07-07       Impact factor: 2.631

8.  Thymectomy for thymoma and myasthenia gravis. A survey of current surgical practice in thymic disease amongst EACTS members.

Authors:  Marco Lucchi; Paul Van Schil; Ralph Schmid; Federico Rea; Franca Melfi; Kalliopi Athanassiadi; Marcin Zielinski; Tom Treasure
Journal:  Interact Cardiovasc Thorac Surg       Date:  2012-02-27

9.  Estimation of incidence, prevalence, and age-at-diagnosis of myasthenia gravis among adults by hospital discharge records.

Authors:  Anett Foldvari; Nora Kovacs; Valeria Sipos; Gabriella Merth; Ferenc Vincze; Maria Szucs; Janos Sandor
Journal:  Wien Klin Wochenschr       Date:  2015-05-20       Impact factor: 1.704

10.  The MGTX experience: challenges in planning and executing an international, multicenter clinical trial.

Authors:  Inmaculada B Aban; Gil I Wolfe; Gary R Cutter; Henry J Kaminski; Alfred Jaretzki; Greg Minisman; Robin Conwit; John Newsom-Davis
Journal:  J Neuroimmunol       Date:  2008-09-15       Impact factor: 3.478

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.